Filtered By:
Drug: Metformin
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 6410 results found since Jan 2013.
Pharmacological and Pathological Effects of Mulberry Leaf Extract on the Treatment of Type 1 Diabetes Mellitus Mice
This study investigated the pharmacological and pathological effects of aqueous mulberry leaf extract on type 1 diabetes mellitus mice induced with an intraperitoneal injection of streptozotocin (STZ). Diabetic mice were randomized into six groups: control (normal group), model, metformin-treated mice, and high-dose, medium-dose, and low-dose mulberry. The mulberry-treated mice were divided into high-, medium-, and low-dose groups based on the various doses of aqueous mulberry leaf extract during gavage. The efficacy of the six-week intervention was evaluated by measuring levels of fasting plasma glucose, alkaline phosphat...
Source: Current Issues in Molecular Biology - July 28, 2023 Category: Molecular Biology Authors: Liru Luo Wei Fan Jingping Qin Shiyin Guo Hang Xiao Zhonghai Tang Source Type: research
Metformin reduces insulin resistance and attenuates progressive renal injury in prepubertal obese Dahl salt-sensitive rats
Am J Physiol Renal Physiol. 2023 Jul 27. doi: 10.1152/ajprenal.00078.2023. Online ahead of print.ABSTRACTPrepubertal obesity (PPO) is currently an epidemic and is considered a major risk factor for renal injury. Previous studies have demonstrated that insulin resistance contributes to renal injury in obesity, independent of diabetes. However, studies examining the relationship between insulin resistance and renal injury in obese children are lacking. Recently, we reported that progressive renal injury in Dahl salt-sensitive leptin receptor mutant (SSLepRmutant) rats was associated with insulin resistance prior to puberty. ...
Source: American Journal of Physiology. Renal Physiology - July 27, 2023 Category: Physiology Authors: Ubong S Ekperikpe Sautan Mandal Stephen J Holt Jacori K Daniels Tyler D Johnson Jonita S Cooper Sarah M Safir Denise C Cornelius Jan M Williams Source Type: research
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
CONCLUSIONS: In conclusion, the administration of once-weekly Semaglutide exhibited a substantial reduction in HbA1c, average systolic blood pressure (SBP), mean diastolic blood pressure (DBP), body weight, waist circumference, body mass index (BMI), and a rise in pulse rate, as opposed to the once-daily administration of Sitagliptin.PMID:37498865 | DOI:10.1080/07853890.2023.2239830
Source: Annals of Medicine - July 27, 2023 Category: Internal Medicine Authors: Tirath Patel Fnu Nageeta Rohab Sohail Tooba Shaukat Butt Shyamala Ganesan Fnu Madhurita Muhammad Ahmed Mahrukh Zafar Wirda Zafar Muhammad Uzair Zaman Giustino Varrassi Mahima Khatri Satesh Kumar Source Type: research
Metformin in type 2 diabetes: Evidence for its beneficial effects on frailty and sarcopenia
Curr Diabetes Rev. 2023 Jul 27. doi: 10.2174/1573399820666230727101141. Online ahead of print.ABSTRACTThis narrative review aimed to discuss the potential interplay among frailty syndrome, sarcopenia and metformin in type 2 diabetes mellitus (T2DM). There is emerging evidence on the potential protective role of metformin on both frailty and sarcopenia. However, results are not always consistent. Thus, further research is needed to provide a definitive answer on any role of metformin in improving frailty and/or sarcopenia in T2DM.PMID:37497698 | DOI:10.2174/1573399820666230727101141
Source: Current Diabetes Reviews - July 27, 2023 Category: Endocrinology Authors: Elisavet E Pyrgioti Nikolaos D Karakousis Petros N Georgakopoulos Nikolaos Papanas Source Type: research
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis
CONCLUSION: The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies.PMID:37499149
Source: Alternative Therapies in Health and Medicine - July 27, 2023 Category: Complementary Medicine Authors: GuangZhi Li Dongmei Zhang Jie Ni Shizhen Wang Source Type: research
Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis
Conclusion: Sulfonylureas and insulin may increase the incidence of pancreatic cancer in diabetic patients, with varying effects observed among different ethnicities (Asian and Western). Due to significant heterogeneity across studies, further interpretation of the relationship between hypoglycemic agents and pancreatic cancer incidence in diabetic patients requires well-adjusted data and better-organized clinical trials.PMID:37497113 | PMC:PMC10366383 | DOI:10.3389/fphar.2023.1193610
Source: Cancer Control - July 27, 2023 Category: Cancer & Oncology Authors: Zimo Zhao Xinyi He Yan Sun Source Type: research
